Vertex Pharmaceuticals
$504.73Change from previous close: −0.40%Absolute change: −$2.01
At a glance
- Revenue growth
- +8.90%
- 2025 vs 2024
- Net margin
- 32.9%
- 2024: -4.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3,631 | -493 | 3,537 | 4,130 | 2,644 | 3,254 | 1,569 | 1,270 | 845 | 236 |
| Depreciation and amortization | 179 | 182 | 170 | 148 | 126 | 110 | 107 | 72.4 | 61.4 | 61.4 |
| Capital expenditure | -438 | -298 | -200 | -205 | -235 | -260 | -75.4 | -95.4 | -99.4 | -56.6 |
| Investing cash flow | -945 | -3,770 | -3,142 | -321 | -341 | 99.4 | -1,235 | -202 | -483 | 51.2 |
| Financing cash flow | -2,261 | -1,495 | -562 | -67.7 | -1,478 | -505 | 127 | -71.2 | 68.4 | 133 |
| Share repurchases | -2,387 | -1,582 | -654 | -172 | -1,561 | -739 | -192 | -350 | — | — |
| Debt issued | — | — | 1.8 | 0.0 | 28.3 | 13.3 | 10.0 | 20.8 | 34.7 | 86.2 |
| Debt repaid | -5.4 | -33.6 | -44.9 | -85.5 | -47.0 | -42.3 | -39.2 | -33.4 | -324 | -93.0 |
| Effect of exchange rates | 90.9 | -42.6 | 26.9 | -29.2 | -13.4 | 20.6 | 1.6 | -6.2 | 5.8 | -4.7 |
| Net change in cash | 516 | -5,800 | -140 | 3,712 | 811 | 2,868 | 462 | 991 | 436 | 416 |
| Free cash flow | 3,194 | -790 | 3,337 | 3,925 | 2,409 | — | — | — | — | — |
| Levered free cash flow | 2,573 | 2,800 | 3,510 | 3,307 | 2,402 | 2,232 | 937 | 887 | 446 | 223 |